Development And Commercialization Agreement With Nxera
28/10/2026 06:02
BRIEF-Idorsia Initiates Pivotal Phase 3 Study For Lucerastat In Fabry Disease And Enters Co-Development And Commercialization Agreement With Nxera Oct 28 (Reuters) - IDORSIA LTD IDIA.S:
IDORSIA INITIATES PIVOTAL PHASE 3 STUDY FOR LUCERASTAT IN FABRY DISEASE AND ENTERS CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT WITH NXERA
NXERA TO HOLD COMMERCIALIZATION RIGHTS FOR LUCERASTAT IN JAPAN AND SELECTED ASIA PACIFIC MARKETS
NXERA TO PAY IDORSIA CHF 7 MILLION AND CONTRIBUTE TO PHASE 3 DEVELOPMENT
Source text: ID:nGNE7F5gBW
Further company coverage: IDIA.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Nxera Pharma
See all newsTable: Nxera Pharma -9-MTH group results (IFRS)
Brief: Nxera Pharma Secures Exclusive Rights To Fabry Disease Phase 3 Oral Therapy Candidate Lucerastat For Japan
Nxera Pharma Secures Exclusive Rights To Fabry Disease Phase 3 Oral Therapy Candidate Lucerastat For Japan And Selected Asia Pacific Markets
Development And Commercialization Agreement With Nxera
Nxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy